Structure Therapeutics INC 8-K filings

Structure Therapeutics reported Q2 2026 financial results, highlighted by the initiation of Phase 3 trials for its oral GLP-1 agonist aleniglipron and a robust cash reserve extending runway through 2028.

Structure Therapeutics Inc. has amended its sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. to remove the aggregate offering amount for its at-the-market (ATM) shares, while also filing a prospectus supplement to increase the aggregate offering price to $400 million.

Structure Therapeutics Inc. announced the appointment of Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026, bringing extensive executive leadership experience in the biopharmaceutical sector.

Structure Therapeutics announced positive topline data from its Phase 2 ACCESS II trial and interim data from supplementary studies for its oral GLP-1 receptor agonist, aleniglipron, demonstrating significant weight loss and improved tolerability.

Structure Therapeutics announced positive Phase 2 aleniglipron data, a robust cash position, and plans for Phase 3 initiation in 2H 2026.

Structure Therapeutics' subsidiary, Gasherbrum Bio, entered a non-exclusive licensing agreement with Genentech and Roche for certain GLP-1 receptor agonist patents, securing a $100 million upfront payment and future royalties.

Structure Therapeutics Inc. announced a follow-on public offering of ADSs and pre-funded warrants, aiming to raise approximately $650 million in gross proceeds.

Structure Therapeutics Inc. announced positive topline data from its ACCESS clinical program for aleniglipron, a once-daily oral GLP-1 receptor agonist, demonstrating significant weight loss and a favorable safety profile.

Structure Therapeutics announced its third-quarter 2025 financial results and provided updates on its oral GLP-1 and amylin receptor agonist programs, including upcoming data readouts and new study initiations.

Structure Therapeutics reports Q2 2025 financial results, highlighting progress in its oral GLP-1 and amylin agonist programs with key data readouts and study initiations on track for year-end.

Structure Therapeutics Inc. announced the successful outcomes of its 2025 Annual General Meeting, where shareholders elected directors, ratified the independent auditor, and approved executive compensation on an advisory basis.

Structure Therapeutics announces Q1 2025 financial results, highlighting progress in clinical trials for its oral small molecule therapeutics and a strong cash position.

Structure Therapeutics announces positive financial results for 2024 and advancements in its obesity treatment pipeline, including the completion of enrollment for Aleniglipron studies and progress with ACCG-2671.

Structure Therapeutics has announced the selection of ACCG-2671, an oral small molecule amylin receptor agonist, as its lead candidate for obesity treatment, with Phase 1 trials expected by the end of 2025.

Structure Therapeutics reports positive progress in their obesity drug development program, including the dosing of first patients in a Phase 2b study, and a strong financial position with $915.3 million in cash.

Structure Therapeutics has appointed a new Chief Medical Officer and a Chief Development Officer as part of a planned executive transition.

Structure Therapeutics Inc. has appointed Angus Russell to its Board of Directors and Audit Committee, effective August 26, 2024.

Structure Therapeutics announced positive results from its Phase 2a obesity study for GSBR-1290 and reported a strong cash position of $927.1 million.

Structure Therapeutics held its 2024 Annual General Meeting, electing Sharon Tetlow as a Class I Director and appointing Ted W. Love, M.D. to the Audit Committee.

Structure Therapeutics has updated its risk factors and provided an outlook on the GLP-1 agonist market, projecting significant growth by 2027.

Structure Therapeutics reports positive topline data from Phase 2a obesity and capsule to tablet PK studies for its oral GLP-1 receptor agonist, GSBR-1290, showing significant weight loss and favorable safety.

Structure Therapeutics announced its first quarter 2024 financial results and provided updates on its clinical programs, including upcoming data readouts and trial initiations.

Structure Therapeutics announced positive clinical trial results for its lead drug candidate and a robust cash position to fund operations through 2026.